InCephalo develops compartment-locked cytokine biologics that activate immune responses directly within brain tumors, avoiding systemic exposure. Their lead candidate, InC01, delivers localized IL‑12 activity with high safety margins, achieving significant tumor regression in preclinical glioblastoma models. The platform targets orphan CNS indications, leveraging EMA orphan drug designation to enable a protected regulatory pathway.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Systemic administration of biologics for brain cancer treatment often results in low drug concentrations at the tumor site due to the blood-brain barrier, while also causing significant systemic exposure and off-target side effects. Local administration improves drug concentration in the brain, but leakage into the bloodstream can still lead to accumulation and toxicity.
Solution
InCephalo is developing Compartment Locked (C-Locked) therapeutics for the treatment of brain cancers. The C-Lock technology retains locally applied biologics within the central nervous system (CNS) and rapidly degrades any molecules that leak into the systemic compartment. This approach aims to maximize drug concentration at the tumor site while minimizing systemic exposure and associated side effects. The technology is applicable to antibodies, Fc-fusion proteins, and similar biological drug formats, enabling the creation of tailor-made molecules for local administration behind the blood-brain barrier.
Target Audience
The primary target audience includes patients with primary and secondary brain cancers, as well as medical professionals specializing in neuro-oncology and drug development for CNS diseases.
Features
- C-Lock technology platform for creating biologics with enhanced CNS retention and rapid systemic degradation
- Tailor-made molecules designed for local administration behind the blood-brain barrier
- Potential for higher local dosing windows with reduced systemic toxicity
- Applicability to various biological drug formats, including antibodies and Fc-fusion proteins
- InC01: a C-Locked IL-12 cytokine drug candidate for the treatment of cancers in the brain with Orphan Drug Designation by EMA
- Aims to transform the "cold" immunosuppressive brain tumor microenvironment into an inflammatory "hotspot"